Update 9/23/2013: Hackers release phone number and address of this scuzzbucket
2) He says he's dropping the price of the drug.
This is what a conniving, evil little son of a bitch looks like
Martin Shkreli is a Albanian American hedge fund manager and entrepreneur, specializing in healthcare businesses and is a co-founder of MSMB Capital Management, of Retrophin, and the founder of Turing Pharmaceuticals .
The former hedge fund manager purchased the rights to a drug that's been used for 62 years to treat parasitic infections, and hiked the price from around $13.50 per tablet to $750 per tablet.
The drug is called Daraprim ,and it is used primarily to treat infants and people who have weakened immune systems — most notably those who have AIDS. It's among the most common treatments for life-threatening parasitic infections.
Shkreli tweeted "Every time a drug goes generic I grieve. Let us not mourn the dearly departed, instead celebrate the profits and new assets it brought us"
Shkreli oversaw Retrophin until last fall, Retrophin alleges that he created the biotech and took it public solely to provide stock to MSMB investors when the hedge fund became insolvent.